+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Trends in mRNA Vaccine Research. Edition No. 1. Trends in Drug Discovery

  • Book

  • 432 Pages
  • January 2025
  • John Wiley and Sons Ltd
  • ID: 5989218
The authoritative guide to the revolutionary concept behind the successful COVID-19 vaccines

In Trends in mRNA Vaccine Research, a team of distinguished researchers delivers a practical and up-to-date discussion of the biochemical and biomedical foundations of mRNA vaccines. They also explore the manufacturing conditions required for successful vaccine development and review recent progress in a variety of medical fields, including vaccines against pathogens like SARS-CoV-2, HIV, plasmodium, Mycobacterium tuberculosis, as well as anticancer vaccines.

Volume highlights include: - A historical overview of mRNA vaccine development- Immune responses to modified or unmodified mRNA vaccines- A description of the different mRNA vaccine platforms- Latest data on current mRNA vaccine developments against infectious diseases and cancer

Perfect for medicinal chemists, immunologists, and epidemiologists, Trends in mRNA Vaccine Research will also benefit researchers and scientists working in the pharmaceutical industry, as well as cancer researchers with an interest in vaccine development.

Table of Contents

PART I: HOW mRNA VACCINES WORK
Historical overview
Immune responses to mRNA vaccines
mRNA vaccine platforms
mRNA delivery and formulation

PART II: REGULATORY QUESTIONS AND CHALLENGES IN VACCINE PRODUCTION
Ethical and regulatory issues
GMP and upscaling of mRNA vaccine production

PART III: mRNA PROPHYLACTIC VACCINES FOR IMMUNITY AGAINST PATHOGENS
SARS-CoV-2
Influenza
CMV, EBV
Flaviviruses
HIV
Rabies
Malaria
Tuberculosis

PART IV: mRNA THERAPEUTIC CANCER VACCINES
Tumor associated antigens
Tumor specific antigens

PART V: mRNA VACCINES FOR TOLERANCE
Atherosclerosis
Multiple sclerosis

Authors

Gabor Tamas Szabo BioNTech SE, Germany. Norbert Pardi BioNTech SE, Germany.